A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES
This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities. Patients will be randomized 1:1 to receive either aleglitazar 150 mcg orally daily or matching placebo.
Inclusion Criteria:
A. Established Type 2 diabetes mellitus (T2D) according to 2010 ADA criteria; treatment may include diet alone, or any glucose-lowering therapies except for thiazolidinediones (TDZs) B. No fulfillment of criterion A) but evidence of glucose abnormalities
Exclusion Criteria:
Fall Rivers, Mississippi 02720, United States
Caba, C1119ACN, Argentina
Caba, C1428DCO, Argentina
Quebec, Prince Edward Island G1V 4G2, Canada
Ste-Foy, Quebec G1W 4R4, Canada
Barranquila, Colombia
Praha 4 - Krc, 140 59, Czechia
Homburg/Saar, 66421, Germany
Sarawak, 94300, Malaysia
Soham, Ely, CB7 5JD, United Kingdom